Oncology Reviews最新文献_第2页

Tracheal Tumors: Clinical Practice Guidelines for Palliative Treatment and Follow-Up. 气管肿瘤：气管肿瘤：姑息治疗和随访临床实践指南》。

IF 3.1

Oncology Reviews Pub Date : 2024-09-18 eCollection Date: 2024-01-01 DOI: 10.3389/or.2024.1451247

Aleksandra Piórek, Adam Płużański, Magdalena Knetki-Wróblewska, Kinga Winiarczyk, Sylwia Tabor, Dariusz M Kowalski, Maciej Krzakowski

{"title":"Tracheal Tumors: Clinical Practice Guidelines for Palliative Treatment and Follow-Up.","authors":"Aleksandra Piórek, Adam Płużański, Magdalena Knetki-Wróblewska, Kinga Winiarczyk, Sylwia Tabor, Dariusz M Kowalski, Maciej Krzakowski","doi":"10.3389/or.2024.1451247","DOIUrl":"10.3389/or.2024.1451247","url":null,"abstract":"A substantial portion of patients with advanced cancer cannot be cured, regardless of the therapeutic methods employed. Hence, rational palliative causal treatment becomes crucial. Representative studies specifically addressing the exclusive palliative treatment of patients diagnosed with tracheal cancers have not been identified. In most studies, patients treated palliatively constituted a subset of the overall evaluated group. A thorough literature review was conducted, focusing on three types of palliative treatment: palliative radiotherapy, palliative surgical procedures, and systemic treatment for advanced disease. This review uniquely fills a significant gap in the existing literature by providing the first comprehensive and updated clinical practice guidelines specifically focused on the palliative treatment of tracheal tumors. The proposed guidelines emphasize the unique clinical challenges and treatment strategies pertinent to palliative care in tracheal tumors, which are not adequately covered in existing guidelines for other thoracic malignancies.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"18 ","pages":"1451247"},"PeriodicalIF":3.1,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers and Facilitators Related to Undertaking Physical Activities in Colorectal Cancer Patients: A Scoping Review. 大肠癌患者参加体育活动的障碍和促进因素：范围界定综述》。

IF 3.1

Oncology Reviews Pub Date : 2024-09-06 eCollection Date: 2024-01-01 DOI: 10.3389/or.2024.1360480

Hu Yan, Chang Shuying, Li Yuege, Kong Han

{"title":"Barriers and Facilitators Related to Undertaking Physical Activities in Colorectal Cancer Patients: A Scoping Review.","authors":"Hu Yan, Chang Shuying, Li Yuege, Kong Han","doi":"10.3389/or.2024.1360480","DOIUrl":"10.3389/or.2024.1360480","url":null,"abstract":"Background: Colorectal cancer (CRC) and its treatments cause significant acute, chronic, or latent adverse effects, leading to decreased physical function and quality of life. Robust evidence supports the positive effects of physical activity (PA) on various health outcomes in CRC patients. However, there is limited understanding regarding the factors that influence PA engagement, including facilitators, preferences, and barriers in this population.Purpose: This scoping review aims to document the breadth and depth of literature concerning the various aspects of PA participation among patients with CRC. We conducted a scoping review of PA among CRC patients.Methods: We searched several databases, including PubMed, Web of Science, Embase, and Cochrane, from their inception to 25 July 2023. Multiple reviewers were involved in all screening and data abstractions. The search yielded 834 individual citations after removing duplicates. After screening the titles and abstracts, 20 articles underwent full-text review, and 11 were included.Results: Our research findings indicate that among CRC patients, the most prevalent facilitators/preferences for PA are understanding its importance and perceiving its benefits, whereas treatment-related effects and lack of time are the most common barriers.Conclusion: CRC patients have unique facilitators and barriers concerning PA. Further research and clinical interventions are required to support and encourage this population to participate in and maintain regular PA.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"18 ","pages":"1360480"},"PeriodicalIF":3.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research Progress on the Mechanism of Histone Deacetylases in Ferroptosis of Glioma. 组蛋白去乙酰化酶在胶质瘤铁变态反应中的作用机制研究进展。

IF 3.1

Oncology Reviews Pub Date : 2024-08-12 eCollection Date: 2024-01-01 DOI: 10.3389/or.2024.1432131

Meng Ma, Xifeng Fei, Dongyi Jiang, Hanchun Chen, Xiangtong Xie, Zhimin Wang, Qiang Huang

引用次数: 0

Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein. 多功能 CRM1 蛋白的新颖和不那么新颖的抑制剂

IF 3.1

Oncology Reviews Pub Date : 2024-08-05 eCollection Date: 2024-01-01 DOI: 10.3389/or.2024.1427497

Waitman K Aumann, Rafi Kazi, Amanda M Harrington, Daniel S Wechsler

引用次数: 0

Cancer-Induced Resting Sinus Tachycardia: An Overlooked Clinical Diagnosis. 癌症诱发的静息窦性心动过速：被忽视的临床诊断。

IF 3.1

Oncology Reviews Pub Date : 2024-08-02 eCollection Date: 2024-01-01 DOI: 10.3389/or.2024.1439415

Minas Sakellakis, Jashan Reet, Michail Kladas, Gregory Hoge, Athanasios Chalkias, Miroslav Radulovic

{"title":"Cancer-Induced Resting Sinus Tachycardia: An Overlooked Clinical Diagnosis.","authors":"Minas Sakellakis, Jashan Reet, Michail Kladas, Gregory Hoge, Athanasios Chalkias, Miroslav Radulovic","doi":"10.3389/or.2024.1439415","DOIUrl":"10.3389/or.2024.1439415","url":null,"abstract":"Elevated resting heart rate is frequently observed in cancer patients, and is associated with increased mortality. Although specific chemotherapeutic agents can induce cardiotoxicity, the presence of sinus tachycardia in chemotherapy-naive patients suggests other factors likely contribute to this clinical presentation. Despite its prevalence, cancer-associated resting sinus tachycardia has not been fully recognized and comprehensively described as a separate clinical entity. Secondary effects of cancer, especially structural cardiac changes, secretory factors (inflammatory cytokines), and thromboembolic disease can cause resting tachycardia. Alternatively, rapid heart rate may reflect compensatory mechanisms responding to increased metabolic demands, raised cardiac output states, and even pain. Hence, cancer-associated tachycardia presents a clinical dilemma; acute life-threatening conditions (such as sepsis, pulmonary embolism, etc.) must be ruled out, but cancer itself can explain resting sinus tachycardia and more conservative management can avoid unnecessary testing, cost and patient stress. Furthermore, identification and management of cardiac conditions associated with cancer may improve survival and the quality of life of cancer patients.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"18 ","pages":"1439415"},"PeriodicalIF":3.1,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-Translational Modification of PTEN Protein: Quantity and Activity. PTEN 蛋白的翻译后修饰：数量与活性。

IF 3.1

Oncology Reviews Pub Date : 2024-07-31 eCollection Date: 2024-01-01 DOI: 10.3389/or.2024.1430237

Xiao Li, Pu Yang, Xiaoli Hou, Shaoping Ji

{"title":"Post-Translational Modification of PTEN Protein: Quantity and Activity.","authors":"Xiao Li, Pu Yang, Xiaoli Hou, Shaoping Ji","doi":"10.3389/or.2024.1430237","DOIUrl":"10.3389/or.2024.1430237","url":null,"abstract":"Post-translational modifications play crucial roles in regulating protein functions and stabilities. PTEN is a critical tumor suppressor involved in regulating cellular proliferation, survival, and migration processes. However, dysregulation of PTEN is common in various human cancers. PTEN stability and activation/suppression have been extensively studied in the context of tumorigenesis through inhibition of the PI3K/AKT signaling pathway. PTEN undergoes various post-translational modifications, primarily including phosphorylation, acetylation, ubiquitination, SUMOylation, neddylation, and oxidation, which finely tune its activity and stability. Generally, phosphorylation modulates PTEN activity through its lipid phosphatase function, leading to altered power of the signaling pathways. Acetylation influences PTEN protein stability and degradation rate. SUMOylation has been implicated in PTEN localization and interactions with other proteins, affecting its overall function. Neddylation, as a novel modification of PTEN, is a key regulatory mechanism in the loss of tumor suppressor function of PTEN. Although current therapeutic approaches focus primarily on inhibiting PI3 kinase, understanding the post-translational modifications of PTEN could help provide new therapeutic strategies that can restore PTEN's role in PIP3-dependent tumors. The present review summarizes the major recent developments in the regulation of PTEN protein level and activity. We expect that these insights will contribute to better understanding of this critical tumor suppressor and its potential implications for cancer therapy in the future.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"18 ","pages":"1430237"},"PeriodicalIF":3.1,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fresh Insights Into SLC25A26: Potential New Therapeutic Target for Cancers: A Review. 对 SLC25A26 的新认识：癌症的潜在新治疗靶点：综述。

IF 3.6

Oncology Reviews Pub Date : 2024-04-30 eCollection Date: 2024-01-01 DOI: 10.3389/or.2024.1379323

Yangheng Xu, Zhisheng Hong, Sheng Yu, Ronghan Huang, Kunqi Li, Ming Li, Sisi Xie, Lvyun Zhu

引用次数: 0

Transplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines 多肽抗肿瘤疫苗研究中的可移植小鼠肿瘤

IF 3.6

Oncology Reviews Pub Date : 2024-01-08 DOI: 10.3389/or.2023.12189

Aleksandr V. Ponomarev, Irina Zh. Shubina, Zinaida A. Sokolova, M. Baryshnikova, V. Kosorukov

引用次数: 0

Multimodal Management of Colorectal Liver Metastases: State of the Art 结直肠肝转移的多模式治疗：最新技术

IF 3.6

Oncology Reviews Pub Date : 2024-01-04 DOI: 10.3389/or.2023.11799

Elisabetta Filoni, Vittoria Musci, Alessia Di Rito, Riccardo Inchingolo, Riccardo Memeo, Francesco Mannavola

{"title":"Multimodal Management of Colorectal Liver Metastases: State of the Art","authors":"Elisabetta Filoni, Vittoria Musci, Alessia Di Rito, Riccardo Inchingolo, Riccardo Memeo, Francesco Mannavola","doi":"10.3389/or.2023.11799","DOIUrl":"https://doi.org/10.3389/or.2023.11799","url":null,"abstract":"Liver is the most common site of colorectal cancer (CRC) metastases. Treatment of CRC liver metastases (CRLM) includes different strategies, prevalently based on the clinical and oncological intent. Valid approaches in liver-limited or liver-prevalent disease include surgery, percutaneous ablative procedures (radiofrequency ablation, microwave ablation), intra-arterial perfusional techniques (chemo-embolization, radio-embolization) as well as stereotactic radiotherapy. Systemic treatments, including chemotherapy, immunotherapy and other biological agents, are the only options for patients with no chance of locoregional approaches. The use of chemotherapy in other settings, such as neoadjuvant, adjuvant or conversion therapy of CRLM, is commonly accepted in the clinical practice, although data from several clinical trials have been mostly inconclusive. The optimal integration of all these strategies, when applicable and clinically indicated, should be ever considered in patients affected by CRLM based on clinical evidence and multidisciplinary experience. Here we revised in detail all the possible therapeutic approaches of CRLM focusing on the current evidences, the studies still in progress and the often contradictory data.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 8","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139386483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges of FGFR2 Testing in Gastric Cancer 胃癌 FGFR2 检测面临的挑战

IF 3.6

Oncology Reviews Pub Date : 2023-12-14 DOI: 10.3389/or.2023.11790

Ilya Tsimafeyeu, G. Raskin

引用次数: 0